China’s NMPA accepts Innovent AmAb application

Nov 13, 2018

China’s National Medical Products Administration accepts Innovent’s application for biosimilar adalimumab. The application seeks approval for the treatment of ankylosing spondylitis, rheumatoid arthritis, and psoriasis.

Print Page Mail Article